BLUEPRINT MEDICINES CORP (BPMC) Stock Fundamental Analysis

NASDAQ:BPMC • US09627Y1091

129.46 USD
+0.18 (+0.14%)
At close: Jul 17, 2025
129.5 USD
+0.04 (+0.03%)
After Hours: 7/17/2025, 8:06:04 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Taking everything into account, BPMC scores 4 out of 10 in our fundamental rating. BPMC was compared to 521 industry peers in the Biotechnology industry. BPMC has a bad profitability rating. Also its financial health evaluation is rather negative. BPMC is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • BPMC had negative earnings in the past year.
  • In the past year BPMC has reported a negative cash flow from operations.
  • BPMC had negative earnings in 4 of the past 5 years.
  • BPMC had negative operating cash flow in 4 of the past 5 years.
BPMC Yearly Net Income VS EBIT VS OCF VS FCFBPMC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M

1.2 Ratios

  • With an excellent Return On Assets value of -13.03%, BPMC belongs to the best of the industry, outperforming 82.55% of the companies in the same industry.
  • BPMC has a Return On Equity of -45.52%. This is in the better half of the industry: BPMC outperforms 67.63% of its industry peers.
Industry RankSector Rank
ROA -13.03%
ROE -45.52%
ROIC N/A
ROA(3y)-31.77%
ROA(5y)-25.69%
ROE(3y)-172.98%
ROE(5y)-112.79%
ROIC(3y)N/A
ROIC(5y)N/A
BPMC Yearly ROA, ROE, ROICBPMC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

  • With an excellent Gross Margin value of 96.48%, BPMC belongs to the best of the industry, outperforming 96.22% of the companies in the same industry.
  • In the last couple of years the Gross Margin of BPMC has grown nicely.
  • The Profit Margin and Operating Margin are not available for BPMC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.19%
GM growth 5YN/A
BPMC Yearly Profit, Operating, Gross MarginsBPMC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • BPMC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, BPMC has more shares outstanding
  • BPMC has more shares outstanding than it did 5 years ago.
  • BPMC has a worse debt/assets ratio than last year.
BPMC Yearly Shares OutstandingBPMC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
BPMC Yearly Total Debt VS Total AssetsBPMC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • BPMC has an Altman-Z score of 3.51. This indicates that BPMC is financially healthy and has little risk of bankruptcy at the moment.
  • BPMC has a Altman-Z score of 3.51. This is in the better half of the industry: BPMC outperforms 74.10% of its industry peers.
  • BPMC has a Debt/Equity ratio of 1.01. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 1.01, BPMC is not doing good in the industry: 76.80% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.01
Debt/FCF N/A
Altman-Z 3.51
ROIC/WACCN/A
WACC10.27%
BPMC Yearly LT Debt VS Equity VS FCFBPMC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

  • BPMC has a Current Ratio of 2.80. This indicates that BPMC is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of BPMC (2.80) is worse than 66.73% of its industry peers.
  • A Quick Ratio of 2.75 indicates that BPMC has no problem at all paying its short term obligations.
  • With a Quick ratio value of 2.75, BPMC is not doing good in the industry: 65.47% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.8
Quick Ratio 2.75
BPMC Yearly Current Assets VS Current LiabilitesBPMC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • BPMC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.24%, which is quite impressive.
  • Looking at the last year, BPMC shows a very strong growth in Revenue. The Revenue has grown by 99.14%.
  • BPMC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 50.23% yearly.
EPS 1Y (TTM)57.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.94%
Revenue 1Y (TTM)99.14%
Revenue growth 3Y41.37%
Revenue growth 5Y50.23%
Sales Q2Q%55.45%

3.2 Future

  • Based on estimates for the next years, BPMC will show a very strong growth in Earnings Per Share. The EPS will grow by 28.63% on average per year.
  • BPMC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.27% yearly.
EPS Next Y76.13%
EPS Next 2Y50.32%
EPS Next 3Y46.02%
EPS Next 5Y28.63%
Revenue Next Year41.72%
Revenue Next 2Y37.18%
Revenue Next 3Y32.66%
Revenue Next 5Y26.27%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BPMC Yearly Revenue VS EstimatesBPMC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
BPMC Yearly EPS VS EstimatesBPMC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 10 -10 20

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BPMC. In the last year negative earnings were reported.
  • A Price/Forward Earnings ratio of 131.18 indicates a quite expensive valuation of BPMC.
  • 87.77% of the companies in the same industry are more expensive than BPMC, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of BPMC to the average of the S&P500 Index (28.06), we can say BPMC is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 131.18
BPMC Price Earnings VS Forward Price EarningsBPMC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BPMC Per share dataBPMC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • A more expensive valuation may be justified as BPMC's earnings are expected to grow with 46.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.32%
EPS Next 3Y46.02%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for BPMC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

BLUEPRINT MEDICINES CORP

NASDAQ:BPMC (7/17/2025, 8:06:04 PM)

After market: 129.5 +0.04 (+0.03%)

129.46

+0.18 (+0.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01
Earnings (Next)07-30
Inst Owners109.31%
Inst Owner Change-87.32%
Ins Owners0.84%
Ins Owner Change0%
Market Cap8.37B
Revenue(TTM)562.12M
Net Income(TTM)-155.73M
Analysts68
Price Target132.96 (2.7%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-24.05%
Min EPS beat(2)-38.05%
Max EPS beat(2)-10.05%
EPS beat(4)2
Avg EPS beat(4)0.22%
Min EPS beat(4)-38.05%
Max EPS beat(4)39.24%
EPS beat(8)6
Avg EPS beat(8)7.49%
EPS beat(12)9
Avg EPS beat(12)6.42%
EPS beat(16)11
Avg EPS beat(16)-9.61%
Revenue beat(2)0
Avg Revenue beat(2)-3.69%
Min Revenue beat(2)-5.77%
Max Revenue beat(2)-1.61%
Revenue beat(4)1
Avg Revenue beat(4)5.58%
Min Revenue beat(4)-5.77%
Max Revenue beat(4)30.77%
Revenue beat(8)5
Avg Revenue beat(8)10.01%
Revenue beat(12)8
Avg Revenue beat(12)15.3%
Revenue beat(16)11
Avg Revenue beat(16)15.01%
PT rev (1m)0.02%
PT rev (3m)3.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-36.4%
EPS NY rev (1m)0%
EPS NY rev (3m)23.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 131.18
P/S 14.89
P/FCF N/A
P/OCF N/A
P/B 24.47
P/tB 24.47
EV/EBITDA N/A
EPS(TTM)-3.22
EYN/A
EPS(NY)0.99
Fwd EY0.76%
FCF(TTM)-2.33
FCFYN/A
OCF(TTM)-2.25
OCFYN/A
SpS8.69
BVpS5.29
TBVpS5.29
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.03%
ROE -45.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.48%
FCFM N/A
ROA(3y)-31.77%
ROA(5y)-25.69%
ROE(3y)-172.98%
ROE(5y)-112.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.19%
GM growth 5YN/A
F-Score3
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 1.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.61%
Cap/Sales 0.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.8
Quick Ratio 2.75
Altman-Z 3.51
F-Score3
WACC10.27%
ROIC/WACCN/A
Cap/Depr(3y)80.73%
Cap/Depr(5y)67.67%
Cap/Sales(3y)3.9%
Cap/Sales(5y)2.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.94%
EPS Next Y76.13%
EPS Next 2Y50.32%
EPS Next 3Y46.02%
EPS Next 5Y28.63%
Revenue 1Y (TTM)99.14%
Revenue growth 3Y41.37%
Revenue growth 5Y50.23%
Sales Q2Q%55.45%
Revenue Next Year41.72%
Revenue Next 2Y37.18%
Revenue Next 3Y32.66%
Revenue Next 5Y26.27%
EBIT growth 1Y60.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.02%
EBIT Next 3Y49.05%
EBIT Next 5Y35.74%
FCF growth 1Y69.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.45%
OCF growth 3YN/A
OCF growth 5YN/A

BLUEPRINT MEDICINES CORP / BPMC FAQ

Can you provide the ChartMill fundamental rating for BLUEPRINT MEDICINES CORP?

ChartMill assigns a fundamental rating of 4 / 10 to BPMC.


What is the valuation status for BPMC stock?

ChartMill assigns a valuation rating of 2 / 10 to BLUEPRINT MEDICINES CORP (BPMC). This can be considered as Overvalued.


Can you provide the profitability details for BLUEPRINT MEDICINES CORP?

BLUEPRINT MEDICINES CORP (BPMC) has a profitability rating of 3 / 10.


How financially healthy is BLUEPRINT MEDICINES CORP?

The financial health rating of BLUEPRINT MEDICINES CORP (BPMC) is 3 / 10.